Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical reports developments in robotic-assisted minimally invasive care, centered on its da Vinci surgical systems, da Vinci 5, da Vinci SP, and Ion Endoluminal System. Company news commonly covers procedure volume, system placements, installed-base growth, instruments and accessories revenue, operating lease placements, and share repurchase activity.
Updates also include FDA clearances that expand indications for Intuitive platforms, such as cardiac procedures for da Vinci 5 and additional procedures for da Vinci SP. News about the company also reflects completed commercial expansion in Europe, including direct operations for da Vinci and Ion distribution in Southern European markets.
Intuitive (Nasdaq: ISRG) reported Q1 2026 results with revenue of $2.77B, up 23% year-over-year, and GAAP net income of $822M ($2.28 diluted). Worldwide procedures grew ~17%; da Vinci placements were 431 systems. Cash and investments totaled $7.98B at quarter-end.
The company repurchased 2.3 million shares for $1.1B, acquired a business, and issued 2026 guidance including ~13.5%–15.5% da Vinci procedure growth and non-GAAP gross margin of 67.5%–68.5%.
Intuitive (NASDAQ:ISRG) completed its acquisition of the da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica and affiliates, expanding direct operations into Italy, Spain, Portugal, Malta, San Marino and associated territories on March 2, 2026.
The business is integrated into Intuitive’s European commercial organization under Senior VP and GM Dirk Barten, adds ~250 employees, and serves a combined installed base of more than 470 da Vinci systems in Italy, Spain and Portugal; Ion launched recently in Italy and Spain.
Intuitive (NASDAQ: ISRG) announced FDA 510(k) clearance of the da Vinci 5 system for selected cardiac procedures on Jan. 26, 2026, expanding indications to include mitral valve repair and IMA mobilization for revascularization.
The release notes over 140,000 prior robotic cardiac procedures globally, a limited U.S. site rollout through 2026 to establish cardiac programs, and system capabilities including 10,000x computing power, instrumentation capturing 1,000+ data points/sec, advanced vessel/perfusion imaging, and an integrated digital ecosystem for planning through analytics.
Intuitive (NASDAQ: ISRG) announced that more than 20 million patients worldwide have undergone surgery using da Vinci systems, a milestone reached at the end of 2025. In 2025 alone, clinicians performed over 3.1 million da Vinci procedures. The company highlighted platform advances including da Vinci 5 (claimed >10,000x computing power), da Vinci Single Port expansion of indications, and Ion robotic bronchoscopy, used in >140,000 lung biopsies in 2025. Intuitive said these volumes inform technology, training, and system improvements aimed at expanding access to minimally invasive care.
Intuitive (Nasdaq: ISRG) reported Q4 2025 results on Jan 22, 2026: revenue $2.87B (+19% YoY), GAAP net income $795M ($2.21/share) and non-GAAP net income $914M ($2.53/share).
Worldwide procedures (da Vinci + Ion) grew ~18%; da Vinci procedures ~17%, Ion procedures ~44%. Company placed 532 da Vinci systems (303 da Vinci 5) and ended Q4 with 11,106 da Vinci systems installed and 995 Ion systems.
Q4 systems revenue was $786M, instruments & accessories $1.66B. Cash, cash equivalents and investments were $9.03B. 2026 outlook: da Vinci procedure growth ~13–15%, non-GAAP gross margin 67–68%, and non-GAAP operating expense growth 11–15%; tariffs estimated to reduce revenue margin by ~1.2%.
Intuitive (Nasdaq: ISRG) reported preliminary unaudited results: Q4 2025 revenue ~$2.87B (+19% YoY) and FY2025 revenue ~$10.06B (+21% YoY). Full‑year da Vinci procedures totaled ~3,153,000 (+18% YoY) and the company placed 1,721 da Vinci systems in 2025 (including 870 da Vinci 5); Q4 placements were 532 systems (303 da Vinci 5). Instruments & accessories revenue was ~$1.66B in Q4 and ~$6.02B for FY2025. Preliminary results include a $70M fourth‑quarter contribution to the Intuitive Foundation. The company expects da Vinci procedures +13%–15% in 2026. Results are unaudited and subject to final closing and audit.
Intuitive (NASDAQ: ISRG) announced that the U.S. Food and Drug Administration cleared the da Vinci Single Port (SP) surgical system on Dec 10, 2025 for use in inguinal hernia repair, cholecystectomy, and appendectomy.
The clearances expand SP’s U.S. indications beyond existing approvals in urology, colorectal, thoracic, and transoral procedures and build on prior international approvals in Europe, Japan, and Korea. The company highlights a supporting evidence base of more than 500 peer-reviewed publications and describes SP as enabling single-incision or natural-orifice access with three multi-jointed instruments and an articulating 3DHD endoscope.
Intuitive (Nasdaq: ISRG) reported Q3 2025 results for the quarter ended Sept 30, 2025. Revenue was $2.51B, up 23% year-over-year. Worldwide procedures (da Vinci + Ion) grew ~20%; da Vinci procedures +19% and Ion +52%. The company placed 427 da Vinci systems (240 da Vinci 5) and 50 Ion systems, growing the da Vinci installed base to 10,763 (+13%) and Ion to 954 (+30%).
GAAP net income was $704M ($1.95 diluted EPS); non-GAAP net income was $867M ($2.40). Repurchased 4.0M shares for $1.92B. Cash and investments ended at $8.43B, down $1.10B.
2025 outlook: da Vinci procedure growth ~17.0–17.5%; non-GAAP gross margin expected 67–67.5% (vs 69.1% in 2024) and non-GAAP OpEx growth 11–13%; tariffs cited as a margin headwind.
Intuitive (NASDAQ:ISRG) announced FDA clearance of a software update for the Ion endoluminal system on Oct 8, 2025. The release adds AI-driven navigation to address CT-to-body divergence and integrates advanced imaging, including tomosynthesis with standard 2D C-arm, to broaden access to real-time imaging during lung biopsies. Features will begin with a limited U.S. launch and a broader U.S. rollout is planned for 2026. As of June 30, 2025, more than 900 Ion systems were installed across 10 countries, and Intuitive is supporting clinical research involving >b>2,000 subjects.
Jupiter Endovascular (ISRG) closed an oversubscribed Series B financing that surpassed its $40 million target, led by Sonder Capital with participation from Senvest Management, LB Investment, and a new strategic corporate investor. Proceeds will fund completion of the SPIRARE II pivotal trial, commercialization preparation, and new TFX applications. The announcement follows an FDA 510(k) clearance last month for the Vertex Catheter with TFX and precedes presentation of first-in-human SPIRARE I results at TCT on October 26, 2025. SPIRARE II plans to enroll up to 145 patients at up to 25 U.S. and European sites.